CPSF1 and prostate carcinoma: Our findings that CPSF1 is upregulated in patients with CRPC, that patients with high CPSF1 expression have worse progression-free survival, and that benign prostate epithelial cells display no growth inhibition from CPSF1 knockdown collectively provide strong evidence for the inhibition of CPSF1 as a therapeutic strategy to treat prostate cancer.